AURA
Price
$7.51
Change
-$0.12 (-1.57%)
Updated
Feb 21 closing price
Capitalization
375.14M
17 days until earnings call
OBIO
Price
$4.72
Change
-$0.48 (-9.23%)
Updated
Feb 21 closing price
Capitalization
178.53M
Ad is loading...

AURA vs OBIO

Header iconAURA vs OBIO Comparison
Open Charts AURA vs OBIOBanner chart's image
Aura Biosciences
Price$7.51
Change-$0.12 (-1.57%)
Volume$146.73K
Capitalization375.14M
Orchestra BioMed Holdings
Price$4.72
Change-$0.48 (-9.23%)
Volume$71.54K
Capitalization178.53M
AURA vs OBIO Comparison Chart
Loading...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AURA vs. OBIO commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a Hold and OBIO is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (AURA: $7.51 vs. OBIO: $4.72)
Brand notoriety: AURA and OBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURA: 97% vs. OBIO: 63%
Market capitalization -- AURA: $375.14M vs. OBIO: $177.02M
AURA [@Biotechnology] is valued at $375.14M. OBIO’s [@Biotechnology] market capitalization is $177.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURA’s FA Score shows that 0 FA rating(s) are green whileOBIO’s FA Score has 0 green FA rating(s).

  • AURA’s FA Score: 0 green, 5 red.
  • OBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, AURA is a better buy in the long-term than OBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AURA’s TA Score shows that 2 TA indicator(s) are bullish while OBIO’s TA Score has 2 bullish TA indicator(s).

  • AURA’s TA Score: 2 bullish, 6 bearish.
  • OBIO’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, OBIO is a better buy in the short-term than AURA.

Price Growth

AURA (@Biotechnology) experienced а -5.53% price change this week, while OBIO (@Biotechnology) price change was -16.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

AURA is expected to report earnings on May 08, 2025.

OBIO is expected to report earnings on Jan 25, 2023.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AURA($375M) has a higher market cap than OBIO($179M). OBIO YTD gains are higher at: 18.000 vs. AURA (-8.637). OBIO has higher annual earnings (EBITDA): -59.81M vs. AURA (-91.84M). AURA has more cash in the bank: 174M vs. OBIO (66.9M). OBIO has less debt than AURA: OBIO (1.84M) vs AURA (19.1M). OBIO has higher revenues than AURA: OBIO (2.65M) vs AURA (0).
AURAOBIOAURA / OBIO
Capitalization375M179M209%
EBITDA-91.84M-59.81M154%
Gain YTD-8.63718.000-48%
P/E RatioN/AN/A-
Revenue02.65M-
Total Cash174M66.9M260%
Total Debt19.1M1.84M1,039%
TECHNICAL ANALYSIS
Technical Analysis
AURAOBIO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
56%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
44%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 5 days ago
59%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
54%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
View a ticker or compare two or three
Ad is loading...
AURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LVOPX18.38N/A
N/A
Lord Abbett Value Opportunities P
NCAVX12.44N/A
N/A
Nuance Concentrated Value Investor
FRIQX12.06N/A
N/A
Fidelity Advisor Real Estate Income M
FLXSX16.22N/A
N/A
Fidelity Flex Small Cap Index
VIDMX9.19N/A
N/A
Virtus KAR Developing Markets I

OBIO and

Correlation & Price change

A.I.dvisor tells us that OBIO and KALV have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OBIO and KALV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OBIO
1D Price
Change %
OBIO100%
-9.23%
KALV - OBIO
33%
Poorly correlated
-5.73%
CALC - OBIO
33%
Poorly correlated
-3.69%
INSM - OBIO
32%
Poorly correlated
-3.05%
RAIN - OBIO
32%
Poorly correlated
-0.75%
GBIO - OBIO
30%
Poorly correlated
-0.78%
More